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CASE REPORT A 46-year-old man presented
with a three-year history ofrhinitis treated with
intranasalcorticosteroids. InJuly 1998heattended
his general practitioner with wheeze and was
diagnosed as suffering from asthma. Treatment
with inhaled salbutamol and beclomethasone
200 mcg twice daily was commenced in
September 1998 and he improved. In January
1999 he presented with recurrent wheeze and
non-productivecough;chestexaminationshowed
bilateral rhonchi. Chest radiograph showed
obviousairspaceconsolidationintheleftmidzone,
with a smaller area in the right midzone and
possiblyafurtherareaattherightapex(Figure 1).
He was commenced on zafirlukast 20 mg twice
daily. Although he had improved at review 8
weeks later, it was noted he had developed a
petechial rash over the lower pretibial area of
both legs. He was changed from zafirlukast to
montelukast. Chest radiograph two weeks
following this review showed resolution of the
previous areas of consolidation but new
consolidation was noted atthe leftbase andright
mid zone (Figure 2). Eosinophil count was noted
tobeelevated at 16.9 x 109/1 (72% eosinophilia).
Theplateletcountwasnormal.Therehadbeenno
reduction in the dose of inhaled corticosteroids
over this period. He was thought to have
pulmonary eosinophilia and was commenced on
prednisolone 40 mg daily for one week with
symptomatic improvement including resolution
of the petechial rash. At review two weeks
following completion of prednisolone, he was
again noted to have a petechial rash, again in a
similar distribution. He complained ofdiarrhoea
five days later and montelukast was stopped. He
continued to complain ofdyspnoea, wheeze and
non-productivecough.Atreviewtwoweekslater,
hecomplainedofincreasingexertionaldyspnoea
and he was commenced on prednisolone 30 mg
daily for one week. Again he symptomatically
improvedandthepetechialrashresolved. Again,
one weekfollowing completion ofprednisolone,
he continued to complain of dyspnoea, wheeze
and cough and was commenced on prednisolone
30 mg daily for five days.
Hewasinitially seenattheChestclinic sixweeks
later, two days after completing a further five-
day course ofprednisolone 30 mg for increasing
dyspnoea. He still complained of dyspnoea and
non-productive cough. There was no other
significant history and inparticular there was no
historyofanyinhaledallergens. Chestradiograph
was normal. He was commenced on fluticasone
1000 mcg twice daily. At review, four weeks
later, his symptoms had improved, but he
complained of recurrence of the rash over both
lowerlimbs. Onexaminationhewasthin. Hehad
a purpuric rash, which was more extensive than
previously,overbothlowerlimbsandparticularly
pretibially. The nasal mucosa was reddened and
inflamedandnasalpolypswerenoted.Respiratory
rate was 15. Chest examination was normal.
There was no otherabnormality on examination.
Spirometry showed an FEVI of 3.941 (108%
predicted) andaFVC of4.731 (104% predicted).
Residual volume was 126% predicted; total lung
capacitywas 108%predictedandresidualvolume/
total lung capacity ratio was 110% predicted.
Transfer factor was 72% predicted.
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Fig 1. Chest radiograph showing obvious airspace
consolidation in the left midzone, with a smaller
area in the right midzone and possibly at the right
apex.
Chest radiograph showed peripheral ill-defined
streaky infiltrates with septal thickening. CT
chest showed bilateral peripheral pulmonary
infiltrates,moreprominentontheright. Creactive
proteinwas31.Eosinophilcountwas 15.0x 1O9/
1 (69% eosinophilia). Plateletcount was normal.
IgE was 1003 lU/i. pANCA was 1:20 however
myeloperoxidase (MPO)wasnegativeindicating
this was a false positive and not significant. The
remainder of the vasculitic and autoimmune
screenwasnormal. Skinbiopsy showedevidence
of necrotising small vessel vasculitis with
eosinophilic infiltration.
Nerveconduction studies showedthatperipheral
nerve conduction was within normal limits.
Transthoracic echocardiographic examination
was normal. Direct urine microscopy showed an
inactive sediment. Renal function was normal.
Churg-Strauss syndrome was diagnosed and the
patient was commenced on prednisolone 60 mg
daily. Withinoneweekhewas clinically well, his
symptoms and the vasculitic rash had resolved
completely. C reactive protein was 5, eosinophil
countwas0.1 x 109/I (1% eosinophilia) andchest
radiograph was normal.
DISCUSSION
Churg-Strauss syndrome is an eosinophilic
necrotisingvasculitis. Thepresenceoffourofsix
defined criteria (asthma, paranasal sinus
abnormalities, mononeuropathy or poly-
neuropathy, non-fixed radiographic pulmonary
infiltrates, eosinophilia > 10% and biopsy
containing blood vessels with extravascular
eosinophils) establishes the diagnosis with a
sensitivity of 85% and a specificity of 99.7%.1
The differential diagnosis of hypereosinophilia
and systemic vasculitis is beyond the scope of
this case report; however this has previously
beencomprehensively reviewed.2 Recentreports
havedescribedChurg-Strausssyndromeinasthma
patients being treated with leukotriene receptor
antagonists. The Committee on Safety of
Medicines has received 63 reports of Churg-
Strauss syndromesince 1963,59sincethe startof
1998. Ofthese, 90% were associated with drugs
usedtotreatasthma, mainly leukotriene receptor
antagonists.3 It has been suggested that these
patients had formes fruste Churg-Strauss
syndrome which was unmasked following
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corticosteroid withdrawal facilitated by the use
ofthe leukotriene receptor antagonists .4 Churg-
Strauss syndrome has also been reported in
patients who have not received maintenance
systemic corticosteroids.4-9 However in all but
one of these reports the patients had received
recent intermittent systemic corticosteroids.9
It is likely that this patient already had Churg-
Strauss syndrome at the time of initial
presentation. At that stage three of the four
required American College of Rheumatology
criteria for the diagnosis of Churg-Strauss
syndrome were present (rhinitis, asthma and
pulmonary infiltrates) but the eosinophil count
was not measured. The skin vasculitis appeared
following the introduction ofzafirlukast. Whilst
the onset of the skin vasculitis could have been
coincidental, the clear temporal relationship
would alsobeconsistentwiththehypothesis that
leukotriene receptor antagonists accelerated the
disease process. This patient had not previously
received any systemic corticosteroids.
Furthermore the dose of inhaled and intranasal
corticosteroid used is lower than thatrecognised
to have a systemic effect. The mechanism by
which leukotriene receptor antagonists cause
Churg-Strauss syndromeisuncertain. Ithasbeen
postulated that leukotriene receptor blockade
which does not inhibit the eosinophilic
chemotactant, leukotriene B4, may result in a
state of eosinophilic activation leading to the
development of Churg-Strauss syndrome.
However, the fact that Churg-Strauss syndrome
has been reported with the 5-lipoxygtrase
inhibitors,whichalsoblockleukotrieneB4,makes
this possibility less likely. Alternatively it is
possible Churg-Strauss syndrome may represent
an idiosyncratic or hypersensitivity reaction to
leukotriene receptor antagonist exposure. In
conclusion this reportprovides evidence thatthe
use ofleukotriene receptorantagonists may play
a part in accelerating Churg-Strauss syndrome.
This case report illustrates that leukotriene
receptor antagonists may trigger Churg-Strauss
syndrome, and that this condition should be
suspected in patients with asthma who develop
marked eosinophilia or other vasculitic features
followingtheintroductionofleukotrienereceptor
antagonists.
C) The Ulster Medical Society, 2001.
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